Mankind Pharma (MANKIND.NS) Stock Price

Mankind Pharma Price

NSE·CLOSED
2,647.00
​
Market closed

Over the last 7 years Mankind Pharma grew revenue by 16.2% annually, reaching 142.78 B INR. Earnings per share have grown at 18.6% per year over the last 7 years. For Mankind Pharma, the net margin of 13.4% is down versus 18.4% a few years ago. At today's price the dividend yield works out to roughly 0.04%. The payout ratio is around 2% of earnings. The consensus 12-month price target for Mankind Pharma is 2,606.10 INR, about 1.5% below where the stock trades today. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus.

Mankind Pharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma business model & stock analysis

Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem.

Frequently asked questions about Mankind Pharma

Analysts currently set an average price target of 2,686.27 INR for the Mankind Pharma stock (median: 2,606.10 INR), implying +1.5 % versus the latest price. The consensus is based on 22 analyst ratings.

22 analysts currently rate the Mankind Pharma stock: 16 recommend buying, 4 holding and 2 selling.

Converted at the current exchange rate, the Mankind Pharma share trades at 25.98 EUR (2,647.00 INR).

The Mankind Pharma share (MANKIND.NS) is listed on 2 stock exchanges, including: NSE (Indien) (MANKIND.NS).

The revenue of Mankind Pharma is 142.78 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Mankind Pharma is 19.13 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mankind Pharma is currently 57.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mankind Pharma stock.

The price-to-sales ratio (P/S) of Mankind Pharma is currently 7.67. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mankind Pharma stock.

The Eulerpool Quality Score for Mankind Pharma is 5/10.

The ISIN of Mankind Pharma is INE634S01028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Mankind Pharma is MANKIND.NS. The ticker symbol is used to trade Mankind Pharma shares on the stock exchange.

Fair ValueTerminal
2,647.00 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
7.73 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
May 9, 2023
ISIN
INE634S01028
Cusip
Y57688114
Market capitalization
1.09 T INRMega Cap
52-Week Range
PEG
3.67
P/E ratio
P/Ee 2027
44.78
P/Ee 2028
36.60
P/Ee 2029
30.15
P/Ee 2030
25.08
P/S
P/Se
6.72
EV/EBIT
42.14
P/B Ratio
6.70
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
8.46 %
Last updated Nov 22, 2026, 3:38 AM

Mankind Pharma Peer Group

Mankind Pharma Ticker

BSE · MANKIND.BONSE INDIA · MANKIND.NS

Mankind Pharma FIGI

MANKIND:IN · BBG001BN0FY3MANKIND:IB · BBG01G9WXG92MANKIND:IS · BBG01G9WXGC8